Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
December 20, 2024 08:00 ET
|
Galectin Therapeutics Inc.
In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placeboWhile...
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
November 18, 2024 08:00 ET
|
Galectin Therapeutics Inc.
Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
November 14, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that...
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
October 15, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
September 30, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis,...
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis,...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
August 13, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
August 01, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
June 04, 2024 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
May 15, 2024 08:00 ET
|
Galectin Therapeutics Inc.
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic...